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Abstract
Introduction: We have demonstrated previously that the intravenous delivery of multipotent adult progenitor cells
(MAPC) after traumatic brain injury affords neuroprotection via interaction with splenocytes, leading to an increase
in systemic anti-inflammatory cytokines. We hypothesize that the observed modulation of the systemic
inflammatory milieu is related to T regulatory cells and a subsequent increase in the locoregional neuroprotective
M2 macrophage population.
Methods: C57B6 mice were injected with intravenous MAPC 2 and 24 hours after controlled cortical impact injury.
Animals were euthanized 24, 48, 72, and 120 hours after injury. In vivo, the proportion of CD4+/CD25+/FOXP3+
T-regulatory cells were measured in the splenocyte population and plasma. In addition, the brain CD86+ M1 and
CD206+ M2 macrophage populations were quantified. A series of in vitro co-cultures were completed to investigate
the need for direct MAPC:splenocyte contact as well as the effect of MAPC therapy on M1 and M2 macrophage
subtype apoptosis and proliferation.
Results: Significant increases in the splenocyte and plasma T regulatory cell populations were observed with MAPC
therapy at 24 and 48 hours, respectively. In addition, MAPC therapy was associated with an increase in the brain
M2/M1 macrophage ratio at 24, 48 and 120 hours after cortical injury. In vitro cultures of activated microglia with
supernatant derived from MAPC:splenocyte co-cultures also demonstrated an increase in the M2/M1 ratio. The
observed changes were secondary to an increase in M1 macrophage apoptosis.
Conclusions: The data show that the intravenous delivery of MAPC after cortical injury results in increases in T
regulatory cells in splenocytes and plasma with a concordant increase in the locoregional M2/M1 macrophage
ratio. Direct contact between the MAPC and splenocytes is required to modulate activated microglia, adding further
evidence to the central role of the spleen in MAPC-mediated neuroprotection.
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Introduction
Traumatic brain injury (TBI) affects nearly 1.5 million
patients in the United States annually [1]. TBI is asso-
ciated with significant long-term physical, cognitive, and
psychosocial deficits leading to an annual economic im-
pact of 60 billion dollars. The prevention of primary
brain trauma has proven to be difficult. Therefore, a
large amount of research is currently underway to inves-
tigate potential treatments that could limit the secondary
injury associated with TBI. One possible pathway to-
wards neuroprotection is via modulation of the proin-
flammatory environment observed after TBI.
The central nervous system (CNS) is a complex ar-
rangement of interacting cells including glia and neu-
rons. Microglia (five to ten percent of the total glial
population) represent the resident immune cells (akin to
tissue macrophages) in the CNS [2]. Early activation of
microglial cells has been observed in both TBI and
spinal cord injury {Chirumamilla, 2002 #27, [3], Beck,
2010 #28, [4]}.
The two citations are as below added to reference sec-
tion and should be numbers 3 and 4 which means the
subsequent numbers in the text for references are
changed.
The number and distribution of cerebral macrophages
(endogenous and exogenous) and global activation after
injury make them a likely candidate effector cell
population.
Following acute injury, microglia are activated and dif-
ferentiate into neurotoxic proinflammatory M1 macro-
phages [5]. Classically activated M1 macrophages are
responsible for the continued production of proinflam-
matory cytokines and potentially cytodestructive sub-
stances. Immediately following TBI, the ratio of M1
(proinflammatory) to M2 (an alternatively activated,
anti-inflammatory subtype) macrophages is typically 1:1,
but as time progresses (Day 3 to Day 7), the ratio favors
the M1 subtype [6]. In addition, an initial decrease in
M2 macrophages with concordant increase in M1
macrophages is observed early after spinal cord injury
[7]. Alteration of the biochemical milieu after injury
is known to activate microglia towards alternate acti-
vation pathways [8]. Anti-inflammatory cytokines such
as interleukin-4 (IL-4) and interleukin-10 (IL-10) have
been shown to lead to preferential differentiation of mi-
croglia into neuroprotective M2 subtype macrophages
[8,9].
Multipotent adult progenitor cells (MAPCs) are
derived from bone marrow [10] and have been asso-
ciated with neuroprotection in a rodent TBI model [11].
Walker et al. [11] showed that the intravenous delivery
of MAPCs after TBI preserved the blood brain barrier,
preserved splenic mass, and increased anti-inflam-
matory cytokine production (IL-4 and IL-10). Further
conclusions indicated that MAPCs interacted with spleno-
cytes leading to an increase in circulating CD4+ T cells
[11].
A subtype of CD4+ T cells (FoxP3+) is known to have
anti-inflammatory properties. We hypothesize that the
observed increase in anti-inflammatory cytokine produc-
tion with MAPC therapy after TBI is secondary to an in-
crease in the FoxP3+ T regulatory cell population. We
hypothesize that the increase in anti-inflammatory cyto-
kines previously demonstrated affects the resident
microglial population leading to an increase in the M2/
M1 macrophage ratio thereby accounting for the
observed neuroprotection. To test our hypothesis a
series of in vivo and in vitro experiments were com-
pleted, using MAPCs in a mouse model of TBI.
Methods
All protocols involving the use of animals were in com-
pliance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and were
approved by the University of Texas Medical School at
Houston’s Institutional Animal Care and Use Committee
(protocol HSC-AWC-10-039).
In vivo experiments
Experimental design
Three groups of C57B6 mice underwent controlled cor-
tical impact (CCI) injury (n = 6/group, 2 groups) or sham
injury (n = 5). Human multipotent adult progenitor cells
(hMAPC), produced under cGMP conditions that have
been previously described [12,13], were provided by
Athersys, Inc. (Cleveland, OH, USA). One group of
injured animals had 1 × 107 MAPC/kg injected via the
tail vein at 2 and 24 hours after CCI injury. Seventy
hours after CCI injury, Evan’s blue dye was injected into
the animal via the tail vein. After 1 hour of circulation,
the animals were euthanized with subsequent
homogenization of the injured cortical hemisphere and
overnight incubation in formamide. Blood brain barrier
(BBB) permeability was determined via measurement of
Evan’s blue absorbance (Figure 1A). In order to measure
splenic mass, two additional groups of C57B6 mice
underwent controlled cortical impact (CCI) injury (CCI
alone and CCI plus MAPC) and sham injury (n = 18/
group, Figure 1B).
An additional seven groups (n = 4/group) of C57B6
mice underwent controlled cortical impact (CCI) injury
(six groups) or sham injury (one group). Three groups of
mice received 1 × 107 MAPC / kg injected via the tail
vein at 2 and 24 hours after CCI injury. One CCI injury
alone control group and one MAPC treated group were
euthanized at 24, 48, and 72 hours, with the sham
injured group being euthanized at 24 hours. At the time
of sacrifice, spleens were harvested and the percentage
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of CD4+/CD25+/FOXP3+ T regulatory cells was mea-
sured by flow cytometry (Figure 1C).
An additional seven groups (n =6/group) of C57 Black
6 mice underwent controlled cortical impact (CCI) in-
jury (six groups) or sham injury (one group). Three
groups of mice received 1 × 107 MAPC / kg injected via
the tail vein at 2 and 24 hours after CCI injury. One CCI
injury alone control group and one MAPC treated group
were euthanized at 24, 48, and 72 hours, with the sham
injured group being euthanized at 24 hours. At the time
of sacrifice, the brain was homogenized, the cell popula-
tions were separated by density separation, and the
CD86+ M1 and CD206+ M2 macrophage populations
were analyzed by flow cytometry (Figure 1D).
Controlled cortical impact injury
A controlled cortical impact (CCI) device (eCCI Model
6.3; VCU, Richmond, VA, USA) was used to administer
a unilateral brain injury as described previously [14].
Male mice weighing 17 to 21 grams were anesthetized
with 4% isoflurane / O2 and the head was mounted in a
stereotactic frame. Animals received a single impact of
1.0-mm depth of deformation with an impact velocity of
5.0 m/sec and a dwell time of 150 msec (moderate-severe
injury), making the impact to the parietal association cor-
tex. Sham injuries were performed by anesthetizing the
animals, making the midline incision, and separating the
skin, connective tissue, and aponeurosis from the cranium.
The incision was then closed [15,16].
Preparation and intravenous injection of MAPCHu-
man MAPCs were obtained from Athersys, Inc. and
stored in liquid nitrogen. Prior to injection, the MAPC
were thawed, washed and resuspended in phosphate buf-
fered saline (PBS). Cells were counted and checked for
viability via Trypan blue exclusion (>95% viability). Im-
mediately prior to intravenous injection, MAPC were
mixed gently eight to ten times to ensure a homoge-
neous suspension. MAPC were injected via the tail vein
at 2 and 24 hours after CCI injury at a dose of 1 × 107
MAPC / kg. Therefore, each treatment animal received
two separate doses of MAPC. CCI alone animals
received PBS vehicle injection alone at the designated in-
jection time points.
Evan’s blue BBB permeability analysis
Seventy-two hours after CCI injury, the mice were
anesthetized as described above, and 0.2 mL of 3%
Evan’s blue dye in PBS was injected via the tail vein. The
animals were allowed to recover for 60 minutes to allow
for perfusion of the dye. After this time, the animals
were euthanized via right atrial puncture and perfused
with 4% paraformaldehyde. Next, the animals were
decapitated followed by brain extraction. The cerebellum
was dissected away from the rest of the cortical tissue.
The brain was divided through the midline and the mass
of each hemisphere (ipsilateral to injury) was measured.
Each hemisphere was then homogenized and allowed to
incubate overnight in 0.9 mL of formamide (Sigma
Aldrich, St. Louis, MO, USA) at 50°C to allow for dye
extraction. After centrifugation, 100 μL of the super-
natant from each sample was transferred to a 96-well
Figure 1 Experimental design for in vivo experiments. Four sets
of experiments were done in order to determine (A) blood brain
barrier, (B) splenic mass, (C) characterization of T-regulatory cells in
spleen and blood, and (D) characterization of local microglia
phenotype using flow cytometry.
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plate (in triplicate) and absorbance was measured at 620
nm using a VersaMax plate reader (Molecular Devices
Inc., Sunnyvale, CA, USA). Samples were run in tripli-
cate and all values were normalized to hemisphere
weight.
Splenocyte isolation and culture
Seventy-two hours after injury, the mice underwent
splenectomy with measurement of splenic mass. Next,
the spleens were minced with a razor blade, washed with
basic media (10% FBS and 1% penicillin/streptomycin in
RPMI), crushed, and filtered through a 100 μm filter.
The effluent sample from the filter was gently titurated
eight to ten times and subsequently filtered through a 40
μm filter to remove any remaining connective tissue,
then centrifuged at 1,000 g for 3 minutes. Next, the
supernatants were removed, samples resuspended in 2
mL of red blood cell lysis buffer (Qiagen Sciences,
Valencia, CA, USA) and allowed to incubate on ice for
5 minutes. Subsequently, the samples were washed
twice with basic media and centrifuged using the afore-
mentioned settings. The splenocytes were counted and
checked for viability by Trypan blue exclusion (>95%
viability).
Blood collection
At the designated time point, mice were anesthetized as
described above. Blood was aspirated via left ventricular
puncture and placed immediately into collection tubes
with sodium heparin (BD Vacutainer, BD, Franklin
Lakes, NJ, USA). Samples were placed on ice. Erythro-
cytes were lysed from the samples using a red blood lysis
solution (BioLegend, San Diego, CA, USA). The samples
were then centrifuged at 1,000 g for 3 minutes, washed
in PBS and resuspended for cell staining (described
below).
Microglia isolation and staining
The side of the brain ipsilateral to the injury was excised,
minced, and mechanically disrupted using a glass
homogenizer. The homogenate was washed and passed
through a 40-μm cell strainer. Microglia were isolated
with a discontinuous Percoll (Sigma) density gradient
separation; briefly, homogenized brains were suspended
in 30% Percoll in Hank’s Buffered Salt Solution (HBSS)
(ρ= 1.039 g/ml), then pipetted over 70% (ρ= 1.091 g/ml)
and 35% (ρ= 1.045 g/ml) Percoll layers and centrifuged
at 1,000 g for 30 minutes at 20°C. Cells were removed
from the 30%/35% and 35%/70% interfaces, washed
twice in 10% fetal bovine serum (FBS) in HBSS, and
resuspended in staining buffer (4% FBS in PBS) for flow
cytometric analysis.
Samples were incubated for 20 minutes with a CD16/
32-Fc receptor blocker (BioLegend, San Diego, CA,
USA) to reduce nonspecific antibody binding. Samples
were then incubated for 30 minutes with surface mar-
kers CD45-APC and CD86-PE (BioLegend, San Diego,
CA, USA), washed with staining buffer, and resuspended
in ice cold 4% paraformaldehyde in PBS. Samples were
incubated for 30 minutes, then washed and resuspended
in staining buffer with 0.1% Triton X-100 for another 30
minutes. Finally, samples were stained with CD206-FITC
(Biolegend, San Diego, CA, USA) for 30 minutes. All
incubations were performed in the dark at room
temperature. Appropriate isotype controls were
prepared.
CD4+/CD25+/FOXP3+ T regulatory cell staining
Peripheral blood and splenocytes from the study animals
were stained using a FOXP3 T regulatory cell staining kit
as per manufacturer’s suggested protocol. (BioLegend,
San Diego, CA, USA). Briefly, erythrocytes were lysed
from the samples using a red blood lysis solution
(BioLegend, San Diego, CA, USA). The samples were
then washed, resuspended, and incubated with CD25-
PE and CD4-FITC for 30 minutes. Samples were then
washed, resuspended, and incubated with fixation/
permeabilization buffer for 30 minutes; this was fol-
lowed by permeabilization buffer for 15 minutes and then
incubation with FOXP3-AlexaFluor647 for 30 minutes.
All incubations were performed at room temperature. Ap-
propriate isotype controls were prepared.
In vitro experiments
Experimental design
We utilized cell culture techniques to delineate whether
supernatant derived from direct contact between
MAPCs and splenocytes (activated by mitogenic plant
lectin Concanavalin A (ConA)) is required to attenuate
the proinflammatory response of activated microglia
(Figure 2). Briefly, we used supernatant derived from
MAPC:splenocyte co-cultures to attenuate the bacterial
endotoxin lipopolysaccharide (LPS) activated microglia.
We then measured proliferation and apoptosis of M1
and M2 subtype microglia/macrophages.
MAPC:splenocyte direct contact (co-culture) and transwell
cultures
Splenocytes were harvested from naive adult mice
(n = 11/group) as described above, immediately placed
into culture, and stimulated with 2 μg/ml of ConA.
MAPC were added at a ratio of 1:1, 1:5, and 1:10
(MAPC:splenocyte) 2 and 24 hours after splenocyte iso-
lation and culture, to mimic the in vivo tail vein injec-
tion of MAPC, in either direct contact (co-culture) or
transwell cultures. There were no differences in the
effects between 1:1 and 1:5 with very little effect at 1:10
(data not shown); therefore a 1:5 MAPC:splenocyte ratio
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was used for all experiments. Finally, 48 hours after sple-
nocyte isolation, the supernatant was removed for use in
in vitro microglial cultures (see Figure 3).
Microglial cultures
Microglia were isolated from sham/uninjured brains
using the protocol described above. After isolation,
microglia were grown for a month in microglial growth
media which consisted of the following: Dulbecco’s
modified Eagle’s/F12 medium with GlutaMAX (DMEM/
F12) supplemented with 10% FBS, 100units/ml penicil-
lin, 100 g/ml streptomycin and 5 ng/ml of granulocyte
macrophage colony stimulating factor (GM-CSF) (415-
ML-010/CF; R&D Systems, Minneapolis, MN, USA).
After reaching confluency, cells were split into multiple-
well plates and activated with 1 μg/ml bacterial endo-
toxin lipopolysaccharide (LPS) for 12 hours before
MAPC:splenocyte co-culture supernatant was added.
The volume ratio of supernatant to microglia culture
was 1:4. Finally, cells were harvested after 72 hours incu-
bation and characterized (M2 versus M1) by flow cyto-
metry as described previously in the methods section
(Figure 3B and 3C).
Immunostaining
To delineate whether microglia/macrophages are changing
immunophenotypes due to injury and subsequent MAPC
treatment, microglia were grown in 8-well chamber slides
as described above. LPS was added 12 hours prior to the
addition of either supernatant derived from splenocytes
alone or MAPC:splenocyte co-culture. After 72 hours, the
cells were fixed with 4% paraformaldahyde (PFA), washed
three times with tris-buffered saline (TBS) (10 minutes),
and then blocked at room temperature for 1 hour with 5%
fetal bovine serum plus 0.25% Triton X-100 in TBS. They
were then incubated with primary antibodies (CD86
(1:250; ab53004; Abcam, Cambridge, MA, USA) and
CD206 (1:250; ab8918; Abcam, Cambridge, MA, USA)) in
0.25% Triton X-100 in TBS overnight at 4°C. Slidewells
were then washed three times (10 minutes) at room
temperature with TBS. Secondary antibodies were used
at a concentration of 1:1,000 in 0.25% Triton X-100 in TBS
(CD206-AlexaFluor488, A11034 and CD86-AlexaFluor568,
A11004; Invitrogen, Carlsbad, CA, USA); samples were
incubated for 3 hours in the dark. Cells were then
washed three times (10 minutes) with TBS, mounted,
and cover-slipped with Fluoromount-G (Southern
Biotech, Birmingham, AL, USA). We counted the
number of cells from three different frames from six dif-
ferent wells from microglia/macrophages exposed to
supernatant from splenocyte culture alone (n = 6) and
seven different wells (three frames/well) from microglia/
macrophages incubated with supernatant derived from
MAPC:splenocyte co-culture (n = 7). We counted the
total number of cells in each well (three frames at 20x)
that stained for M1 and M2, M1 only, or M2 only.
Figure 2 Schematic setup of in vitro MAPC, splenocyte, and microglia/macrophage interactions. (A) Isolated splenocytes are activated
with 2 μg/ml of ConA. Two hours after isolation, MAPC were added at a ratio of 1:5 (MAPC:splenocyte) in co-culture or transwell cultures. 24
hours after the first dose of MAPCs, a second dose of MAPCs were added at the same ratio. 48 hours after the splenocyte harvest, supernatants
were collected from each specific condition. (B) The supernatant was then used to stimulate LPS-activated microglia. (C) Microglia/macrophages
were characterized via flow cytometry, immunostained or measured for proliferation using the MTS proliferation assay. LPS, lipopolysaccharide;
MAPCs, multipotent adult progenitor cells; MTS.
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In order to determine if supernatant from MAPC:sple-
nocyte co-cultures results in apoptosis of microglia/
macrophages, we used LPS-activated microglia with and
without supernatant treatment (as described above).
Cells were immunostained with CD206 (1:250; ab8918;
Abcam, Cambridge, MA, USA), CD86 (1:100; 550542;
BD Pharmingen, San Jose, CA, USA) and cleaved cas-
pase 3 (CC3), an apoptotic marker (1:1,500; 9664; Cell
Signaling, Beverly, MA, USA). Secondary antibodies
were used at a concentration of 1:1,000 in 0.25% Tri-
ton X-100 in TBS (CD206-AlexaFluor488, A11029,
CD86-AlexaFluor350, A21093 and CC3-AlexaFluor568,
A11011; Invitrogen, Carlsbad, CA, USA). Incubation
periods, washes, and mounting were done as described
above. We counted the total number of cells from eight
different wells (seven frames/well at 10x magnification)
from microglia/macrophages incubated with super-
natant derived from MAPC:splenocyte co-cultures
(n = 8) and from microglia/macrophages exposed to
splenocytes alone (n = 8). We compared the number of
double positive (M1/CC3 or M2/CC3) cells and the num-
ber of triple positive cells between these two groups.
MTS proliferation assay
In order to determine whether supernatant derived from
MAPC:splenocytes co-cultures results in the attenuation
Figure 3 Effect of MAPC:Splenocyte co-culture supernatant on stimulated microglial immunophenotype. (A) Samples of microglial
cultures were first gated on forward- and side-scatter characteristics to exclude debris, electronic noise, and aggregates (not shown). Resulting
populations were then gated to exclude a small number of artifacts displaying extremely high signal for either CD206-AF488 or CD86-PE. Rather
than divide this microglia population further by imposing strict boundaries on a continuous expression pattern, mean fluorescence intensity (MFI,
listed in each box) of the entire remaining population was then determined for each marker and the CD206/CD86 MFI ratio (M2:M1 ratio)
calculated. (B) There was a significant increase in the M2:M1 ratio when the microglia received the supernatant derived from MAPC:splenocyte
co-culture plus LPS when compared to microglia which only received LPS alone, or supernatant derived from MAPC:splenocyte transwell cultures
plus LPS. ** represents P <0.01. LPS, lipopolysaccharide; MAPC, multipotent adult progenitor cell.
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of microglia proliferation, we utilized the CellTiter 96™
Aqueous Non-Radioactive Cell Proliferation Assay
(Promega, Madison, WI, USA). Microglia were activated
with LPS for 12 hours prior to the addition of supernatant
derived from MAPC:splenocyte co-cultures or splenocyte
alone cultures. After 72 hours, the cell proliferation assay
was performed. Briefly, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2 H-tetrazolium,
inner salt (MTS) was added to 96-well plates at a ratio of
20 μl combined MTS/PMS solution per 100 μl culture
medium. After the addition of MTS, the plates were incu-
bated at 37°C for one hour and the plates were subse-
quently read on the VersaMax plate reader (Molecular
Devices Inc., Sunnyvale, CA, USA) at 490 nm absorbance.
Flow cytometry
Data was acquired using a LSR II flow cytometer (BD
Biosciences, San Jose, CA, USA) and analyzed using
FACSDiva software (BD Biosciences, San Jose, CA,
USA). Unless otherwise indicated, 10,000 events of the
gated population of interest were collected for analysis.
Data analysis
Unless otherwise indicated, all values are represented as
mean ± SEM. Values were compared using analysis of
variance (ANOVA) with a post-hoc Dunnet’s test. If only
two groups were compared, either an unpaired t-test or
the Mann–Whitney test was used, as indicated. A P
value of ≤0.05 was used to denote statistical significance.
Results
MAPC treatment after injury attenuates blood brain
barrier permeability
BBB permeability measurement was completed using
Evan’s Blue dye in all three groups [sham (n = 5), CCI
alone (n = 6) and CCI plus MAPC (n = 6)]. Figure 4
demonstrates the mean absorbance (nm) normalized to
tissue weight (grams) derived from homogenized cortical
tissue from the hemisphere ipsilateral to the CCI injury.
The cerebellum was not included in the measurement.
Mice showed an increase in BBB permeability after CCI
alone (0.98 ± 0.09) that was reversed by the intravenous
injection of MAPC (0.72 ± 0.06, P <0.05, CI 0.006 to
0.523). In addition, there were significant differences be-
tween CCI alone (0.98 ± 0.09) and sham (0.46 ± 0.03,
P <0.01, CI 0.257 to 0.518). There were no significant
differences between sham and CCI plus MAPC (CI −0.002
to 0.259).
MAPC treatment after injury preserves splenic mass
Seventy-two hours after CCI injury, mice (n = 18/group)
were euthanized and spleens harvested and weighed. A
significant decrease in mass (P ≤0.01, CI 0.005 to 0.033
grams) is observed in the CCI alone (0.075 ± 0.003
grams) (range 0.044 to 0.098 grams) when compared to
CCI plus MAPC (0.094 ± 0.004 grams) (range 0.690 to
0.137 grams). There was no difference (P= 0.15, CI
0.005 to 0.023 grams) between sham (0.084 ± 0.006
grams) (range 0.055 to 0.150 grams) and CCI plus
MAPC groups.
MAPC treatment after injury increases T regulatory cells
in spleen and peripheral blood
CD4+/CD25+/FOXP3+ T regulatory cells were character-
ized in the spleen and blood of mice at 24, 48, and 72
hours after CCI injury (n = 4/group). There was a signifi-
cant increase in T regulatory cells as a percentage of
CD4+ T helper cells within the spleens of MAPC treated
mice at 24 hours (P ≤0.01), with no difference seen at 48
or 72 hours (Figure 5A). In peripheral blood, percent T
regulatory cells from MAPC treated mice was signifi-
cantly higher at 48 hours after CCI injury (P ≤0.01)
(Figure 5B).
Microglia/macrophages activation phenotype is
influenced by MAPC treatment after injury
Microglia/macrophages were harvested from the brain
after cortical injury in mice at 24, 48, 72, and 120 hours
after CCI injury (n = 6/group). There were significant
increases in the ratio of M2 versus M1 mean fluores-
cence intensity between the CCI plus MAPC versus CCI
alone at 24 (P ≤0.05), 48 (P ≤0.01) and 120 hours
(P ≤0.01) after injury (Figure 6).
Figure 4 MAPC treatment reduces BBB permeability after TBI.
BBB permeability measurement was completed using Evan’s blue
dye as mean absorbance (nm) normalized to tissue weight (grams)
derived from homogenized cortical tissue derived from the
hemisphere ipsilateral to the CCI injury. Mice showed an increase
in BBB permeability after CCI alone that was reversed by the
intravenous injection of MAPC. * represents P <0.05 and
*** represents P <0.005. BBB, blood brain barrier; MAPC, multipotent
adult progenitor cell; TBI, traumatic brain injury.
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Soluble factor(s) modulate microglia phenotype
In order to determine whether direct contact of MAPC
with splenocytes was required to regulate macrophage
phenotype, we evaluated the effect of supernatant
derived from direct co-culture versus transwell cultures
on activated microglia differentiation. After 72 hours of
incubation with supernatant derived from the coculture
or transwell cultures, the populations of CD86+ M1
macrophages and CD206+ M2 macrophages were mea-
sured using flow cytometry. There was a significant in-
crease in the M2:M1 ratio when the microglia received
the supernatant (2.4 ± 0.23) derived from MAPC:spleno-
cyte co-culture plus LPS when compared to microglia
which only received LPS alone (1.24 ± 0.28; P ≤0.05:
Figure 7), or supernatant derived from MAPC:spleno-
cyte transwell cultures plus LPS (1.61 ± 0.28).
Soluble factor(s) attenuate microglia proliferation
We next evaluated whether the increase in the M2:M1 ratio
was secondary to alteration in proliferation. There was a
significant reduction in proliferation of microglia as deter-
mined by absorbance of MTS (P ≤0.01: n=8, Figure 8) in
the microglia treated with supernatant derived from
MAPC:splenocyte co-culture when compared to splenocyte
only culture.
Figure 5 MAPC treatment increases CD4+/CD25+/FOXP3+
cells after TBI in spleen and blood. (A) Measurement of CD4+/
CD25+/FOXP3+ cells was completed in the splenocytes at 24, 48,
and 72 hours after CCI injury and CCI injury plus MAPC (n = 4/
group). There was a significant increase in T regulatory cells as a
percentage of CD4+ T helper cells within the spleens of MAPC
treated mice at 24 hours (P ≤0.01), with no difference seen at 48 or
72 hours. (B) In peripheral blood, percent T regulatory cells from
MAPC treated mice was significantly higher at 48 hours after CCI
injury (P ≤0.01). Of note, there is an additional control of sham
(uninjured: white bar) for baseline profile of splenocytes.
* represents P <0.05 and ** represents P <0.01. CCI, controlled
cortical impact; MAPC, multipotent adult progenitor cell; TBI,
traumatic brain injury.
Figure 6 MAPC treatment changes macrophage/microglia
phenotype after TBI. Graph of the ratio of anti-inflammatory
microglia versus proinflammatory microglia as determined by flow
cytometry. Measurement of brain CD86+ M1 and CD206+ M2
macrophages was completed after cortical injury in mice at 24, 48,
72, and 120 hours after CCI injury (n = 6/group). There were
significant increases in the ratio of M2 versus M1 mean fluorescence
intensity between the CCI plus MAPC versus CCI alone at 24
(P ≤0.05), 48 (P ≤0.01) and 120 hours (P ≤0.01) after injury* represents
P <0.05 and ** represents P <0.01. CCI, controlled cortical impact;
MAPC, multipotent adult progenitor cell; TBI, traumatic brain injury.
Figure 7 Supernatant derived from MAPC:splencocyte co-
cultures attenuates LPS induced proliferation. There was a
significant reduction in proliferation of microglia as determined by
absorbance of MTS (P ≤0.01: n = 8) in the microglia treated with
supernatant derived from MAPC:splenocyte co-culture when
compared to splenocyte only culture. ** represents P <0.01. LPS,
lipopolysaccharide; MAPC, multipotent adult progenitor cell; MTS.
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Soluble factor(s) increase anti-inflammatory microglia/
macrophages
Next, we wanted to determine whether microglia/
macrophages were changing their immunophenotype
due to supernatant derived from MAPC:splenocyte
co-culture or supernatant from splenocyte cultures
alone. Most of the cells were positively labeled for
both (>90% in both groups), but there was a signifi-
cant decrease in the double positive microglial cells
(CD86+ and CD206+) in the MAPC:splenocyte co-
culture group (splenocyte alone: 98.1 ± 0.75 versus
MAPC:splenocyte co-culture: 92.3 ± 2.2, P ≤0.05,
Figure 9A, D). There were significantly more CD206+
cells in the MAPC:splenocyte co-culture group as
opposed to the splenocyte alone group (splenocyte
alone: 0.73 ± 0.48 versus MAPC:splenocyte co-culture:
7.1 ± 2.1, P ≤0.05, Figure 9 C,E). There were less
CD86+ microglia in the MAPC:splenocyte co-culture
Figure 8 Supernatant derived from MAPC:splencocyte co-cultures promotes anti-inflammatory phenotype of microglia/macrophages.
(A) Graph of percentage of M1/M2 activated with LPS and incubated with MAPC:splenocyte co-culture supernatant versus splenocyte culture
supernatant (without MAPC). A significant decrease in the double positive microglial cells (CD86+ and CD206+) is seen in the MAPC:splenocyte
co-culture group (P ≤0.05). (B) Fewer CD86+ microglia were observed in the MAPC:splenocyte co-culture group, but this change was not
significant. (C) Significantly more CD206+ cells were observed in the MAPC:splenocyte co-culture group as opposed to the splenocyte alone
group (P ≤0.05). (D) Photomicrograph of isolated microglia/macrophages activated LPS and splenocyte alone (without MAPC) supernatant. Note
the number of dual stained cells. (E) Photomicrograph of isolated microglia/macrophages activated LPS and incubated with MAPC:splenocyte co-
culture supernatant treatment. Note the number of M2 cells (green). M2 cells are labeled green and M1 cells are labeled red. * represents P <0.05.
LPS, lipopolysaccharide; MAPC, multipotent adult progenitor cell.
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group, but this change was not significant (splenocyte
alone: 1.1 ± 0.8 versus MAPC:splenocyte co-culture:
0.6 ± 0.4, Figure 9B).
Soluble factor(s) increase apoptosis of proinflammatory
microglia/macrophages
There was a significant decrease in the total apoptosis when
cells were treated with supernatant from MAPC:splenocyte
co-cultures. Triple positive microglia (CD86+/CD206+/CC3+)
significantly decreased after treatment with super-
natant derived from MAPC:splenocyte co-cultures
(splenocyte alone: 60.2 ± 3.7 versus MAPC:splenocyte
co-culture: 43.9 ± 2.7, P ≤0.01, Figure 3A,D). There
was a significant increase in M1 microglial cell apop-
tosis as measured by the number of CD86+/CC3+
microglia in microglia treated with supernatant derived
Figure 9 Supernatant derived from MAPC:splenocyte co-cultures promotes apoptosis of proinflammatory microglia/macrophages.
(A) Triple positive microglia (CD86+/CD206+/CC3+) significantly decreased after treatment with supernatant derived from MAPC:splenocyte
co-cultures (P ≤0.01). (B) A significant increase in M1 microglial apoptosis was measured by the number of CD86+/CC3+ microglia in microglia
treated with supernatant derived from MAPC:splenocyte co-cultures (P ≤0.05). (C) No significant difference in the number of CD206+/CC3+
microglia between the two groups was observed. (D) Photomicrograph of isolated microglia/macrophages activated LPS and splenocyte alone
(without MAPC) supernatant. Note the number of triple stained cells. (E) Photomicrograph of isolated microglia/macrophages activated LPS
and incubated with MAPC in direct contact with splenocytes supernatant treatment. Note the number of M1/CC3 as indicated by arrows.
M2 positive cells are labeled green, CC3 positive cells are labeled red, and M1 positive cells are labeled blue * and ** represents P <0.05. LPS,
lipopolysaccharide; MAPCs, multipotent adult progenitor cells.
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from MAPC:splenocyte co-cultures (splenocyte alone:
0.0 ± 0.0 versus MAPC:splenocyte co-culture: 2.7 ± 1.0,
P ≤0.05, Figure 3B,E). There was no significant difference
in the number of CD206+/CC3+ microglia between the
two groups (splenocyte alone: 13.9± 2.8 versus MAPC:
splenocyte co-culture: 14.6± 8.8, P= 1, Figure 3C).
Discussion
Our data show that the neuroprotective effect of intra-
venous MAPC therapy is associated with an alteration in
the ratio of brain microglia phenotypes from neuroin-
flammatory to neuroprotective. Localization of MAPCs
within the spleen with concordant preservation of
splenic mass prior to the observed alteration of the in-
nate immune response points to the pivotal role of
MAPC:splenocyte interaction. The time course studies
of T-regulatory cells agree with in vitro characterizations
to support the concept that soluble factors dependent
upon MAPC:splenocyte direct contact influence the ap-
pearance of T regulatory cells. Known temporal and ana-
tomic anti-inflammatory stimuli provide insight into
association of these potential mechanisms of action of
the observed MAPC mediated neuroprotection.
Activated microglia/macrophages have been shown to
be important mediators of injury after TBI [15]. Previ-
ously, we have shown that the intravenous delivery of
MAPC after TBI preserved the BBB, preserved splenic
mass, and increased anti-inflammatory cytokine produc-
tion (IL-4 and IL-10). Interestingly, an increase in the
number and proliferation of CD4+ T cells was found to
be present in the spleens of treatment animals [11]. This
pattern of findings led us to evaluate a potential role for
CD4+/CD25+/FOXP3+ T-regulatory cells, a subtype of
CD4+ T cells with known anti-inflammatory properties,
as being potential mediators of neuroprotection. In
addition, we have previously shown that in the absence
of a spleen (surgical splenectomy prior to injury), TBI
did not induce a severe breach in the BBB as compared
to the animals who did not undergo pre-injury splenec-
tomy. Our hypothesis was also bolstered by recent work
demonstrating a potential protective role of T-regulatory
cells in stroke and neurodegenerative diseases (S. Savitz
et al. unpublished observations) and reports suggesting
that T regulatory cells may work in part by altering
macrophage phenotype [16]. In these experiments we
have demonstrated that the increase in splenic T-
regulatory cells correlated with a shift in the post-TBI
brain microglia phenotype to a predominantly anti-
inflammatory (M2) subtype (Figures 3, 5 and 7A,C).
Fischer et al. demonstrated that intravenously injected
progenitor cells initially were trapped in the spleen in
addition to the lungs [17]. Subsequently, Walker et al.
traced intravenously injected MAPC to the white pulp of
the spleen in close approximation with the blood vessels
suggesting an interaction of MAPC with the resident
splenic lymphocyte population [11]. The in vivo data
demonstrates an initial increase in splenic T-regulatory
cells at 24 hours following intravenous injection of
MAPC (Figure 5A), further supporting the notion of dir-
ect interaction of splenocytes and MAPC. In addition,
our in vitro data supports direct contact between spleno-
cytes and MAPC as necessary for modulation of the
microglia/macrophages towards an anti-inflammatory
phenotype (see Figure 10).
In a non-injured brain microglia could be regulated by
T regulatory cells (Figure 3A). After traumatic brain in-
jury, there is activation of resident microglia and
infiltration of macrophages due to the damaged blood
brain barrier, similar to an injured spinal cord [7]. This
may be directed by proinflammatory effector T cells
(Figure 10B). The main focus of these activated proin-
flammatory myeloid cells is to phagocytose damaged
cells such as neurons and clear other cellular debris. The
infiltrating macrophages could be activated within the
vasculature and/or in the injured microenvironment
with complex interactions among effector T cells and
resident microglia [18]. In addition to activation from a
resting state, resident microglia/macrophages could also
be proliferating. Our in vitro results presented here dem-
onstrate that microglia proliferate after LPS stimulation
(Figure 9), and proliferation is known to be associated with
the proinflammatory phenotype of microglia/macrophage.
With MAPC treatment, we observe a significant over-
all reduction in proliferation of microglia/macrophages
(Figure 8). MAPC:splenocyte derived supernatant treat-
ment also decreases overall apoptosis while significantly
increasing apoptosis of M1 microglia (Figure 3B) as mea-
sured by cleaved caspase 3. In addition to an increase in
apoptosis of proinflammatory M1 microglia, we also
observed an increase in proliferation of the anti-
inflammatory M2 phenotype (Figure 3C) with MAPC
treatment. Thus MAPC treatment (via soluble factors)
influences the microglia/macrophages towards an over-
all anti-inflammatory direction in culture. In vivo,
MAPC treatment results in a significant increase of
CD4+/CD25+/FOXP3+T regulatory cells after 24 hours in
the spleen (Figure 5A) and 48 hours in the blood
(Figure 5B). Further in vivo characterization of local
microglial apoptosis/proliferation and the pathways and
mediators involved is an important next step in clarifying
the mechanism of progenitor cell mechanism after TBI.
Expansion and deployment of these cells could be import-
ant in earlier mitigation of proinflammatory signals closer
to the site of injury via anti-inflammatory Treg cytokine
secretion. Furthermore, changes in microglia/macrophage
may also occur due to direct contact between T-cells and
microglia/macrophages. Molecules such CD11A, CD4,
CD86 and major histocompatibility complex class II
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molecules (MHCII) are all possible points of direct inter-
action between T-cells and microglia [18].
In summary, these findings establish the importance of
cell therapy to systemically attenuate microglia/macro-
phage-induced inflammation after TBI. Our data show
that the intravenous injection of bone marrow-derived
MAPC increases the percentage of T regulatory cells
within the spleen. The observed increased in T regu-
latory cells could potentially modulate the systemic
inflammatory response leading to preferential differenti-
ation of microglial/macrophage cells into the neuropro-
tective M2 phenotype. The in vitro data support the
concept that soluble factors influenced by MAPC:sple-
nocyte interactions affect microglia/macrophages by
decreasing overall proliferation and apoptosis, by specif-
ically increasing apoptosis of proinflammatory microglia
and converting microglia/macrophages towards an anti-
inflammatory phenotype. Overall, we believe that our
data again confirm the central role of splenocytes in the
observed neuroprotection seen with progenitor cell ther-
apy, thereby providing further evidence that the trans-
planted cells afford benefit via a systemic rather than
localized effect.
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